<?xml version="1.0" encoding="UTF-8"?><MedicinalProductIndication xmlns="http://hl7.org/fhir"><id value="example"/><meta><tag><system value="http://terminology.hl7.org/CodeSystem/v3-ActReason"/><code value="HTEST"/><display value="test health data"/></tag></meta><text><status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: example</p><p><b>diseaseSymptomProcedure</b>: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\nor knee replacement surgery.\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). <span>(Details : {http://ema.europa.eu/example/indicationasdisease-symptom-procedure code 'Venousthromboembolismprophylaxis' = 'Venousthromboembolismprophylaxis)</span></p><p><b>comorbidity</b>: Hipsurgery <span>(Details : {http://ema.europa.eu/example/comorbidity code 'Hipsurgery' = 'Hipsurgery)</span></p><p><b>intendedEffect</b>: PRYLX <span>(Details : {http://ema.europa.eu/example/intendedeffect code 'PRYLX' = 'PRYLX)</span></p><p><b>population</b>: </p></div></text><diseaseSymptomProcedure><coding><system value="http://ema.europa.eu/example/indicationasdisease-symptom-procedure"/><code value="Venousthromboembolismprophylaxis"/></coding><text value="Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\nor knee replacement surgery.\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients)."/></diseaseSymptomProcedure><comorbidity><coding><system value="http://ema.europa.eu/example/comorbidity"/><code value="Hipsurgery"/></coding></comorbidity><intendedEffect><coding><system value="http://ema.europa.eu/example/intendedeffect"/><code value="PRYLX"/></coding></intendedEffect><population><ageRange><low><value value="18"/><unit value="a"/></low></ageRange></population></MedicinalProductIndication>